Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IFN-induced antiviral protein that mediate cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus, and dengue virus by inhibiting the early step(s) of replication. Additionally we are shipping IFITM1 Antibodies (109) and and many more products for this protein.
Showing 6 out of 7 products:
Identification of three distinct mutations that converted IFITM1 or IFITM3 (show IFITM3 Proteins) from inhibitors to enhancers of MERS-CoV or SARS (show SARS Proteins)-CoV spike protein-mediated entry revealed key structural motifs or residues determining the biological activities of IFITM proteins.
Epithelial-mesenchymal transition (EMT (show ITK Proteins)) signature was dysregulated by both loss and gain of function of IFITM1, which was partially reverted by Caveolin-1 (CAV1 (show CAV1 Proteins)).
These results indicate that IFITM1 protein can restrict alphavirus infection by inhibiting viral fusion with cellular membranes.
The transcriptional regulation of IFITM1, 2 and 3 expression.
IFITM1 and IFITM3 (show IFITM3 Proteins) inhibit Zika virus infection early in the viral life cycle.
IFITM1 suppression blocks proliferation and invasion of aromatase (show CYP19A1 Proteins) inhibitor-resistant breast cancer in vivo by JAK (show JAK3 Proteins)/STAT1 (show STAT1 Proteins)-mediated induction of p21 (show CDKN1A Proteins).
Compared with CD10 (show MME Proteins), IFITM1 has superior performance distinguishing endometrial stroma of adenomyosis from mesenchyma surrounding invasive endometrial adenocarcinoma.
Overexpression of IFITM1 is associated with Oral Squamous Cell Carcinomas.
High expression of IFITM1 is associated with poor prognosis of colorectal cancer.
These findings indicate that overexpression of IFITM1 enhances the aggressive phenotype of triple-negative SUM149 IBC cells and that this effect is dependent on STAT2 (show STAT2 Proteins)/BRG1 (show SMARCA4 Proteins) interaction.
the importance of the C-terminal region of IFITM1 in modulating the antiviral function through controlling protein subcellular localization.
Palmitoylation of IFITM1 regulates protein stability by preventing proteasomal degradation, and modification of the nonconserved cysteine at the IFITM1 C terminus supports an intramembrane topology with implications for anti-influenza A virus activity.
the fact that IFITM1 can function as a negative regulator of cell proliferation, and because the gene maps to chromosome band 11p15.5, previously associated with NSCLC, it is likely that IFITM1 in man has a key role in tumor formation
Fragilis2 regulates epithelialization of the somites and paraxial mesoderm formation.
The antiproliferative action of IFN-gamma (show IFNG Proteins) requires the induction of IFITM1.
IFN-induced antiviral protein that mediate cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus, and dengue virus by inhibiting the early step(s) of replication. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53- dependent manner. Implicated in the control of cell growth. Component of a multimeric complex involved in the transduction of antiproliferative and homotypic adhesion signals.
interferon-induced transmembrane protein 1
, interferon induced transmembrane protein 1 (9-27)
, interferon induced transmembrane protein 1
, dispanin subfamily A member 2a
, interferon-induced protein 17
, interferon-inducible protein 9-27
, leu-13 antigen
, fragilis protein 2
, ifitm-like protein 2
, interferon induced transmembrane protein 2 like
, interferon-induced membrane protein Leu-13/9-27
, interferon-induced transmembrane protein 1 (9-27)
, interferon-induced transmembrane protein 1 (9-27) isoform 1